Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Procter & Gamble, Johnson & Johnson Among 9 Companies To Announce Dividend Increases In The First Half Of April
10:45pm, Saturday, 28'th Mar 2026
Procter & Gamble is set to announce its 70th consecutive year of dividend growth in April, joining an elite group of long-term dividend growers. I anticipate PG's dividend increase will be 3–5%, sli
Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies Nearly 60% of adolescents treated with ICOTYDE achie
Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength
04:46pm, Friday, 27'th Mar 2026
Johnson & Johnson shows relative strength with a bull flag breakout attempt, supported by key moving averages, signaling improving demand and potential upside toward higher Fibonacci extension targets
2 Stocks I Plan to Hold for the Next 20 Years
04:00pm, Friday, 27'th Mar 2026
One is a diversified healthcare giant with a vast product lineup and an impressive dividend program. The other is a niche leader with a lineup and pipeline that should help it perform well through 204
Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?
10:16am, Friday, 27'th Mar 2026
JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results.
Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
10:22am, Thursday, 26'th Mar 2026
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026
10:06am, Thursday, 26'th Mar 2026
JNJ's rapid pipeline progress and new drug approvals in 2025 set the stage for stronger growth impact from its expanding portfolio in 2026.
Johnson & Johnson $JNJ Shares Sold by Assenagon Asset Management S.A.
03:04am, Thursday, 26'th Mar 2026
Assenagon Asset Management S.A. cut its stake in Johnson and Johnson (NYSE: JNJ) by 69.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange
Johnson & Johnson: Deserves A Place In Conservative Dividend Growth Portfolios
09:43pm, Wednesday, 25'th Mar 2026
Johnson & Johnson demonstrates a robust historical dividend growth profile, highlighted by 63 years of consecutive hikes. JNJ has an AAA credit rating, adding safety for the dividend. Though there are
Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing
06:46pm, Wednesday, 25'th Mar 2026
Johnson & Johnson (JNJ) closed the most recent trading day at $239.93, moving +1.98% from the previous trading session.
How Much Monthly Income Does a $1 Million Portfolio Produce at Age 65?
12:47pm, Wednesday, 25'th Mar 2026
Turning 65 with $1 million saved puts you in a position most Americans will likely never reach, but hitting this number is only half the work. The more important question is what that $1 million actua
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
12:01pm, Tuesday, 24'th Mar 2026
JNJ stock holds strong above key SMAs for 8 months as Innovative Medicine strength, new drugs and MedTech gains fuel momentum despite patent and legal risks.
Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet
10:31am, Tuesday, 24'th Mar 2026
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi
08:45am, Tuesday, 24'th Mar 2026
Protagonist Therapeutics earns a Buy rating, driven by Icotyde's FDA approval and robust near-term commercialization catalysts. Icotyde, the first oral IL-23 receptor antagonist for plaque psoriasis,
